Evidence map›Paper›PMID 36001424›Full record

ArticleAddiction biology2022

Betel quid: New insights into an ancient addiction.

Clare Stokes, Jose A Pino, D Walker Hagan, Gonzalo E Torres, Edward A Phelps, Nicole A Horenstein, Roger L Papke

Open access · greenAbstract read
In one paragraph

Article in Addiction biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Clare StokesDepartment of Pharmacology and Therapeutics, University of Florida, Gainesville, Florida, USA.
Jose A PinoDepartment of Medicine, School of Medicine, University of Atacama, Copiapó, Chile.ORCID 0000-0002-1542-0660
D Walker HaganDepartment of Biomedical Engineering University of Florida, Gainesville, Florida, USA.
Gonzalo E TorresDepartment of Molecular, Cellular, and Biomedical Sciences, City University of New York School of Medicine at City College, New York, New York, USA.
Edward A PhelpsDepartment of Biomedical Engineering University of Florida, Gainesville, Florida, USA.ORCID 0000-0001-8666-805X
Nicole A HorensteinDepartment of Chemistry, University of Florida, Gainesville, Florida, USA.
Roger L PapkeDepartment of Pharmacology and Therapeutics, University of Florida, Gainesville, Florida, USA.ORCID 0000-0002-4468-8658
University of Florida · USCity College of New York · USUniversity of Atacama · CL

Funding

Targeting of Alpha7 nAChR for therapeutic effectsR01GM057481 · NIGMS · UNIVERSITY OF FLORIDA · PI PAPKE, ROGER L · 2000 to 2023
$7.6M
Mechanism and dynamics of islet GABA signalingR01DK124267 · NIDDK · UNIVERSITY OF FLORIDA · PI PHELPS, EDWARD · 2021 to 2025
$1.8M
NIDDK NIH HHS R01 DK124267NIGMS NIH HHS R01 GM057481
6 · The paper itself

Abstract

The use of areca nuts (areca) in the form of betel quids constitutes the fourth most common addiction in the world, associated with high risk for oral disease and cancer. Areca is a complex natural product, making it difficult to identify specific components associated with the addictive and carcinogenic properties. It is commonly believed that the muscarinic agonist arecoline is at the core of the addiction. However, muscarinic receptor activation is not generally believed to support drug-taking behaviour. Subjective accounts of areca use include descriptions of both sedative and stimulatory effects, consistent with the presence of multiple psychoactive agents. We have previously reported partial agonism of α4-containing nicotinic acetylcholine receptors by arecoline and subsequent inhibition of those receptors by whole areca broth. In the present study, we report the inhibition of nicotinic acetylcholine receptors and other types of neurotransmitter receptors with compounds of high molecular weight in areca and the ability of low molecular weight areca extract to activate GABA and glutamate receptors. We confirm the presence of a high concentration of GABA and glutamate in areca. Additionally, data also indicate the presence of a dopamine and serotonin transporter blocking activity in areca that could account for the reported stimulant and antidepressant activity. Our data suggest that toxic elements of high molecular weight may contribute to the oral health liability of betel quid use, while two distinct low molecular weight components may provide elements of reward, and the nicotinic activity of arecoline contributes to the physical dependence of addiction.

Indexed as

Behavior, AddictiveReceptors, NicotinicArecaArecolinegamma-Aminobutyric AcidArecolinegamma-Aminobutyric AcidReceptors, Nicotinicaddictionantidepressantsareca nutbetel quidGABAnicotinic receptors

Identifiers

PMID36001424
PMCPMC9552247
OpenAlexW4291148462

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.